Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-04-18 Sale | 2023-04-19 4:07 pm | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer | 2,532 | $6.5749 | $16,648 | 140,676 (Direct) | View |
| 2023-01-10 Sale | 2023-01-11 4:05 pm | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer | 7,825 | $5.24 | $41,003 | 143,208 (Direct) | View |
| 2022-04-19 Sale | 2022-04-21 4:04 pm | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer | 4,062 | $35.37 | $143,673 | 151,033 (Direct) | View |
| 2022-01-11 Sale | 2022-01-13 4:05 pm | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development | 3,965 | $48.51 | $192,340 | 121,793 (Direct) | View |
| 2021-12-10 Sale | 2021-12-13 5:53 pm | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development | 7,500 | $51.46 | $385,948 | 230,758 (Direct) | View |
| 2021-04-16 Sale | 2021-04-20 4:00 pm | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development | 3,275 | $83.3 | $272,809 | 64,800 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-01-18 Option Award | 2024-01-19 8:37 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer | 223,750 | $0 | 223,750 (Direct) | View |
| 2023-07-19 Option Award | 2023-07-20 5:18 pm | N/A 2033-07-18 | CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer | 375,000 | $0 | 375,000 (Direct) | View |
| 2023-02-06 Option Award | 2023-02-07 4:13 pm | N/A 2033-02-05 | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer | 425,000 | $0 | 425,000 (Direct) | View |
| 2022-01-25 Option Award | 2022-01-27 4:37 pm | N/A 2032-01-24 | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Chief Medical Officer | 86,360 | $0 | 208,153 (Direct) | View |
| 2021-12-10 Exercise | 2021-12-13 5:53 pm | N/A 2029-04-15 | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development | 7,500 | $0 | 230,758 (Direct) | View |
| 2021-12-10 Exercise | 2021-12-13 5:53 pm | N/A N/A | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development | 7,500 | $16.32 | 230,758 (Direct) | View |
| 2021-11-19 Option Award | 2021-11-22 5:38 pm | N/A N/A | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye Senior VP Clinical Development | 60,958 | $0 | 125,758 (Direct) | View |
Ownership | 2021-04-02 4:32 pm | N/A N/A | FATE THERAPEUTICS INC | FATE | Chu Yu-Waye See Remarks | 0 | $0 | 277,426 (Direct) | View |